ROCKET PHARMACEUTICALS INC. 2024-2025 Proxy Voting Records

Description as filed by funds: Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockholders in 2026, or until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: David P. Southwell

ROCKET PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: David P. Southwell”): 55,352,568 for, 23,786,280 withheld, per its Form 8-K filed June 18, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 70% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 63 asset managers below reported 17,043,543 for, 9,694,685 withheld, 0 abstained.

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

Description as filed by funds: Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockholders in 2026, or until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Carsten Boess

ROCKET PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Carsten Boess”): 78,224,283 for, 914,565 withheld, per its Form 8-K filed June 18, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 63 asset managers below reported 26,738,085 for, 143 withheld, 0 abstained.

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

Description as filed by funds: Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockholders in 2026, or until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Fady Malik, M.D., Ph.D.

ROCKET PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Fady Malik, M.D., Ph.D.”): 78,249,290 for, 889,558 withheld, per its Form 8-K filed June 18, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 63 asset managers below reported 26,738,228 for, 0 abstained.

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

Description as filed by funds: Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockholders in 2026, or until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Gotham Makker, M.D.

ROCKET PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Gotham Makker, M.D.”): 73,798,301 for, 5,340,547 withheld, per its Form 8-K filed June 18, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 93% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 63 asset managers below reported 24,510,325 for, 2,227,903 withheld, 0 abstained.

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

Description as filed by funds: Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockholders in 2026, or until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Gaurav Shah, M.D.

ROCKET PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Gaurav Shah, M.D.”): 78,411,712 for, 727,136 withheld, per its Form 8-K filed June 18, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.0% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 63 asset managers below reported 26,738,228 for, 0 abstained.

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

Description as filed by funds: Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockholders in 2026, or until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Mikael Dolsten, M.D., Ph.D.

ROCKET PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Mikael Dolsten, M.D., Ph.D.”): 76,051,973 for, 3,086,875 withheld, per its Form 8-K filed June 18, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 63 asset managers below reported 24,358,883 for, 2,379,345 withheld, 0 abstained.

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

Description as filed by funds: Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockholders in 2026, or until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Pedro Granadillo

ROCKET PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Pedro Granadillo”): 73,571,818 for, 5,567,030 withheld, per its Form 8-K filed June 18, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 93% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 63 asset managers below reported 25,875,339 for, 862,889 withheld, 0 abstained.

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

Description as filed by funds: Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockholders in 2026, or until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Piratip Pratumsuwan

ROCKET PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Piratip Pratumsuwan”): 78,595,512 for, 543,336 withheld, per its Form 8-K filed June 18, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.3% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 63 asset managers below reported 26,738,228 for, 0 abstained.

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

Description as filed by funds: Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockholders in 2026, or until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Roderick Wong, M.D.

ROCKET PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Roderick Wong, M.D.”): 78,146,900 for, 991,948 withheld, per its Form 8-K filed June 18, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 63 asset managers below reported 26,710,384 for, 27,844 withheld, 0 abstained.

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

Description as filed by funds: Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockholders in 2026, or until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Elisabeth Bjork, M.D., Ph.D.

ROCKET PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Elisabeth Björk, M.D., Ph.D.”): 76,976,311 for, 2,162,537 withheld, per its Form 8-K filed June 18, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 59 asset managers below reported 24,927,391 for, 1,035,146 withheld, 0 abstained.

Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.

Description as filed by funds: Consider and act upon a non-binding, advisory vote on the compensation of our named executive officers;

ROCKET PHARMACEUTICALS INC.’s own tally for this item (“3. Non-Binding Advisory Vote on the Compensation of the Company's Named Executive Officers”): 77,186,221 for, 1,437,605 against — passed, per its Form 8-K filed June 18, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal Three - Non-Binding Advisory Vote on the Compensation of the Company's Named Executive Officers The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers, as disclosed in the 2025 Proxy Statement pursuant to Section 14…”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 62 managers: 26,737,431 for, 797 against, 0 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 172 managers: 63,447,236 for, 696,599 against, 201,916 abstained, 77,356 not voted. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: Ratification of the appointment of EisnerAmper LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025;

ROCKET PHARMACEUTICALS INC.’s own tally for this item (“2. Ratification of Appointment of Independent Registered Accounting Firm”): 90,696,301 for, 141,826 against — passed, per its Form 8-K filed June 18, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal Two - Ratification of Appointment of Independent Registered Accounting Firm The Company's stockholders ratified the appointment of EisnerAmper LLP as the Company's independent registered accounting firm for the fiscal year ending December 31, 2025 by the following votes:”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 63 asset managers below reported 26,738,118 for, 110 against, 0 abstained.

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.